Skip to content

Should these particular pharmaceutical shares be considered necessary investments at this moment?

Pharmaceutical stocks may provide rewards for income-focused investors. Two notable contestants, unexpectedly holding slightly lower valuations, could be worth consideration.

Pharmaceutical shares can present dividend-seeking investors with potential, lucrative prospects....
Pharmaceutical shares can present dividend-seeking investors with potential, lucrative prospects. Two notable competitors, currently offering attractive prices, are worth considering.

Should these particular pharmaceutical shares be considered necessary investments at this moment?

In the realm of pharmaceutical stocks, dividend investors can find enticing opportunities. Two notable competitors currently boast attractive pricing.

The biotech and pharmaceutical market is famed for its potential rewards and risks. Developing a new drug involves years of time, substantial upfront expenses, and growth primarily driven by anticipation. However, there are stocks that have thrived on the exchange due to a diverse pipeline of treatments and offer attractive dividends to investors.

AbbVie's Unwavering Dividend Growth

AbbVie, a prominent dividend biotech, has consistently increased its dividend payments for an astounding 52 years. In February 2025, its dividend yield momentarily hovered around 3.3%. The stock experienced a slump due to the loss of exclusivity for its most profitable drug, Humira. However, the company is on the mend with two successor drugs, Skyrizi and Rinvoq, and is expected to generate revenue of $32 billion by 2027, surpassing Humira's peak.

AbbVie (WKN: A1J84E)

Is Amgen a Present-Day Bargain?

Amgen's dividend growth trajectory also looks promising. The company increased its payouts by a staggering 201% over the past decade, offering a dividend yield of approximately 3.3%. This is significantly higher than the S&P 500 average of 1.3%. However, Amgen recently faced a setback due to results from a clinical study for MariTide, a weight reduction drug, which caused the stock to plummet by over 12%. Despite not fully recovering in over a year, the stock's long-term potential, coupled with its dividend, remains appealing for investors. Amgen's pipeline includes 13 drugs that generate over $1 billion in combined revenue, including treatments for high cholesterol and thyroid diseases. A drug failure is not catastrophic for the company, and Amgen is already working on a comeback.

Amgen (WKN: 867900)

Amgen, despite recent setbacks, presents an appealing opportunity for dividend investors based on several key factors:

  • Dividend Stability and Growth: Amgen has boosted its quarterly dividend by 6% to $2.38 per share, resulting in a dividend yield of approximately 3.5%. This is higher than its five-year average yield of about 3.2% and above the large-cap healthcare sector average[1][5]. The company has a record of increasing dividends for 12 consecutive years, demonstrating consistency and commitment to shareholders[3].
  • Dividend Safety and Payout Ratio: Analysts consider Amgen’s dividend secure, backed by solid earnings and anticipated growth. The payout ratio is crucial for ensuring dividend sustainability; Amgen's payout ratio is around 45%, which is low, indicating ample room to maintain or even increase dividends without financial strain. This contrasts with older payout figures like 82.64%, which may reflect differing calculation methods or timeframes, but the lower current ratio offers reassurance[3][5].
  • Stock Valuation and Upside Potential: Analysts predict a 19% upside in Amgen's stock price, indicating undervaluation and potential for appreciation, thereby enhancing total returns for dividend investors[5]. The price-to-earnings (P/E) ratio stands at about 20.5, suggesting reasonable pricing in the healthcare sector, further bolstering its appeal as a potential bargain buy[2].

In conclusion, Amgen combines a solid and growing dividend yield with a robust earnings base ensuring dividend safety and potential stock price appreciation. These factors make it an attractive investment for dividend hunters seeking stable income and some capital upside, even amid recent challenges.

  1. The financial stability and growth potential of Amgen's dividend, coupled with its competitive pricing, make it an appealing option for investors interested in the finance sector.
  2. Amgen's low payout ratio, along with its substantial upfront earnings and anticipated growth, provide a strong foundation for its dividend sustainability and offer an attractive dividend investment opportunity in the finance realm.

Read also:

    Latest